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Both, mammalian cells and microbes have an essential need for iron, which is required for
many metabolic processes and for microbial pathogenicity. In addition, cross-regulatory
interactions between iron homeostasis and immune function are evident. Cytokines and
the acute phase protein hepcidin affect iron homeostasis leading to the retention of the
metal within macrophages and hypoferremia. This is considered to result from a defense
mechanism of the body to limit the availability of iron for extracellular pathogens while
on the other hand the reduction of circulating iron results in the development of anemia
of inﬂammation. Opposite, iron and the erythropoiesis inducing hormone erythropoietin
affect innate immune responses by inﬂuencing interferon-gamma (IFN-γ) mediated (iron)
or NF-kB inducible (erythropoietin) immune effector pathways in macrophages. Thus,
macrophages loaded with iron lose their ability to kill intracellular pathogens via IFN-γ
mediated effector pathways such as nitric oxide (NO) formation. Accordingly, macrophages
invaded by the intracellular bacterium Salmonella enterica serovar Typhimurium increase
the expression of the iron export protein ferroportin thereby reducing the availability of
iron for intramacrophage bacteria while on the other side strengthening anti-microbial
macrophage effector pathways via increased formation of NO orTNF-α. In addition, certain
innate resistance genes such as natural resistance associatedmacrophage protein function
(Nramp1) or lipocalin-2 exert part of their antimicrobial activity by controlling host and/or
microbial iron homeostasis. Consequently, pharmacological or dietary modiﬁcation of
cellular iron trafﬁcking enhances host resistance to intracellular pathogens butmay increase
susceptibility tomicrobes in the extracellular compartment and vice versa.Thus, the control
over iron homeostasis is a central battleﬁeld in host–pathogen interplay inﬂuencing the
course of an infectious disease in favor of either the mammalian host or the pathogenic
invader.
Keywords: iron, anemia of chronic disease, bacteria, nitric oxide, interferon, hepcidin, macrophage
INTRODUCTION
The control over iron homeostasis is decisive in host–pathogen
interaction (Schaible and Kaufmann, 2004; Nairz et al., 2010;
Cassat and Skaar, 2013). This is due to the fact that iron is cen-
tral for several metabolic processes for both, prokaryotic and
eukaryotic cells that the metal affects microbial proliferation and
pathogenicity and in addition signiﬁcantly impacts on immune
cell plasticity and innate immune responses. These multiple func-
tional aspects of iron are based on its ability to transfer electrons
needed during metabolic processes and to catalyze the formation
of highly reactive radicals (Papanikolaou and Pantopoulos, 2005;
Koskenkorva-Frank et al., 2013). The latter can act as signaling
molecules but also intoxicate microbes or damage surrounding
cells and tissues. Many microbes are highly dependent on a suf-
ﬁcient supply of iron and take up this metal by multiple and
divergent pathways or steel it from iron deposition sites of the
host (Winkelmann, 2002; Cassat and Skaar, 2013; Frawley et al.,
2013). The activation and expression of such microbial iron
acquisition systems is linked to their pathogenicity and prolif-
eration (Rabsch et al., 1999; Schrettl et al., 2004; Crouch et al.,
2008; Andrews-Polymenis et al., 2010; Cassat and Skaar, 2013).
On the other hand, iron plays important roles in anti-microbial
host responses, ﬁrst by synergistic effects towards anti-microbial
radical formation (Mastroeni et al., 2000; Esposito et al., 2003;
Papanikolaou and Pantopoulos, 2005; Koskenkorva-Frank et al.,
2013) but second, by directly altering immune cell prolifera-
tion and anti-microbial immune effector pathways (Nairz et al.,
2010). Thus, the host immune system affects the availabil-
ity of iron for microbes via the activity of cytokines, cellular
proteins/peptides and hormones to gain control over pathogen
proliferation and to strengthen speciﬁc immune effector path-
ways, a strategy for which the term “nutritional immunity has
been coined.
ALTERATION OF IRON HOMEOSTASIS DURING INFECTION
AND INFLAMMATION
The most frequent and best known example visualizing the inter-
action between iron, immunity and infection is anemia of chronic
disease (ACD) also termed as anemia of (chronic) inﬂamma-
tion (Cartwright, 1966; Spivak, 2002; Weiss and Goodnough,
2005). ACD is considered to be the second most frequent anemia
worldwide and it develops speciﬁcally in patients suffering from
chronic inﬂammatory diseases, such as auto-immune disorders,
cancer, chronic infections or in patients undergoing dialysis (Weiss
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and Goodnough, 2005). The underlying pathophysiology involves
mainly (i) iron retention within the monocyte/macrophage sys-
tem, (ii) a blunted formation and activity of the red blood cell
hormone erythropoietin (Epo), and (iii) an impaired prolifera-
tion and differentiation of erythroid progenitor cells (Weiss and
Schett, 2013). All these pathophysiological pathways are driven
by inﬂammatory signals, and the mononuclear-phagocyte sys-
tem (MPS) is in the center of such alterations. Speciﬁcally,
macrophages are of central importance for maintaining a sufﬁ-
cient supply of iron for erythropoiesis due to their role in iron
re-utilization from senescent erythrocytes which are taken up by
these immune cells by a process called erythrophagocytosis before
being degraded leading to recovery of heme which is further pro-
cessed by the enzyme heme oxygenase-1 (HO-1) yielding equal
amounts of iron, biliverdin and carbon-monoxid (Delaby et al.,
2005; Knutson et al., 2005; Soe-Lin et al., 2009). Under physi-
ological conditions iron recycling by macrophages accounts for
approximately 95% of the daily needs of the metal for erythro-
poiesis and other physiological processes (Hentze et al., 2010;
Pantopoulos et al., 2012). However, during inﬂammation this
process is blunted resulting in an impaired delivery of iron for
erythropoiesis. Thereby, cytokines and acute-phase proteins affect
body iron homeostasis and macrophage iron metabolism leading
to an inﬂammation driven diversion of iron trafﬁc which is char-
acterized by low circulating iron concentrations and high levels of
the iron storage protein ferritin , the latter reﬂecting iron retention
in the MPS (Thomas and Thomas, 2005; Weiss and Goodnough,
2005).
In case of an infection, auto-immune disease or cancer immune
cells are activated and produce a myriad of cytokines, some of
which exerting speciﬁc effects on iron homeostasis. Cytokines
such as interleukin (IL)-1, IL-6, or IL-22 as well as bacterial LPS
or endoplasmic reticulum stress induce the formation of the mas-
ter regulator of iron homeostasis, hepcidin, in the liver (Nemeth
et al., 2003; Vecchi et al., 2009; Armitage et al., 2011). Hepcidin
affects cellular iron homeostasis upon binding to the only known
iron export protein ferroportin, thereby leading to ferroportin
internalization and degradation which subsequently reduces cel-
lular iron export (Nemeth et al., 2004b). As a consequence of
this interaction, the absorption of iron from the diet is reduced
due to hepcidin mediated reduction of ferroportin expression in
enterocytes, thereby resulting in a reduction of circulating iron
levels which is further aggravated by the inhibition of iron export
from macrophages by the same mechanism (Nemeth et al., 2004a;
Kemna et al., 2005; Roy et al., 2007; Theurl et al., 2009). Moreover,
macrophages produce minute amounts of hepcidin in response
to inﬂammatory stimuli such as IL-6 or LPS thereby blocking
iron export in an autocrine fashion (Peyssonnaux et al., 2006;
Theurl et al., 2008), which is meant to result from a nutritional
immune strategy of the body to reduce the availability of iron for
extracellular pathogens (Figure 1).
In parallel, cytokines exert subtle and hepcidin indepen-
dent effects on the regulation of iron homeostasis on multiple
levels (Weiss and Schett, 2013). First, tumor necrosis factor-
alpha (TNF-α) impairs duodenal iron absorption by an as yet
not fully elucidated mechanism (Johnson et al., 2004). Sec-
ond, TNF-α, IL-1, IL-6, and interferon-gamma (IFN-γ) affect
macrophage iron homeostasis by different avenues. They increase
the uptake of transferrin and non-transferrin bound iron by
modulating the expression of transferrin receptor-1 and diva-
lent metal transporter-1, respectively (Byrd and Horwitz, 1993;
Fahmy and Young, 1993; Mulero and Brock, 1999; Ludwiczek
et al., 2003). In parallel, based on damaging of erythrocytes
by inﬂammation born radicals, the half-life of erythrocytes
decreases and erythrophagocytosis is stimulated. In addition,
many of these cytokines as well as the anti-inﬂammatory cytokines
IL-4, IL-10, and IL-13 promote efﬁcient iron storage within
macrophages/monocytes by increasing the expression of ferritin,
both at the transcriptional and posttranscriptional level (Byrd
and Horwitz, 1993; Weiss et al., 1997a; Mulero and Brock, 1999;
Arosio and Levi, 2002; Tilg et al., 2002; Ludwiczek et al., 2003).
Macrophage iron content is further expanded via an inhibitory
effect of IFN-γ and LPS on ferroportin transcription thereby
reducing cellular iron egress (Yang et al., 2002; Ludwiczek et al.,
2003).
In summary the combination of these regulatory effects lead to
iron retention in circulating monocytes and macrophages which
present with low ferroportin expression and increased intracellu-
lar ferritin levels (Theurl et al., 2006) along with a reduction of
circulating iron concentration, the diagnostic hallmark of ACD.
INTERRELATIONSHIP BETWEEN IRON AVAILABILITY, INNATE
IMMUNE FUNCTION AND CONTROL OF INFECTIONS
Considering the prevalence of ACD the question arises whether
there is a speciﬁc beneﬁt for the host upon development of ACD.
Obviously, the retention of iron in themonocyte–macrophage sys-
tem reduces circulating iron levels and thus the availability of this
essential nutrient for extracellularmicrobes (Figure 1A). This iron
withholding strategy appears to be of beneﬁt to combat infections
with circulating microbes or pathogens residing in tissues with
high iron contents such as the liver (Ganz, 2009;Weinberg, 2009).
In addition, the pathophysiological mechanisms underlying the
development of ACD also signiﬁcantly impact on the efﬁcacy of
host responses against infections. First, the reduced biological
activity of Epo may ameliorate anti-bacterial immune responses.
This is based on the fact that the major erythropoiesis stimulating
hormone Epo also exerts effects on cells and tissues outside the
bone marrow, and such effects are transduced by a heterodimeric
receptor which differs from the receptor expressed on erythroid
progenitor cells (Brines and Cerami, 2012). Thereby, Epo inhibits
pro-inﬂammatory immune effector pathways in macrophages via
inhibition of NF-kB activationwhich results in reduced expression
of inducible nitric oxide synthase (iNOS), TNF-α, IL-6, and IL-12
by inﬂammatory macrophages and an impaired immune control
of infections with bacteria such as Salmonella enterica serovar
typhimurium (S. typhimurium; Nairz et al., 2011). Accordingly,
the reduced Epo activity observed in ACD results in a sustained
pro-inﬂammatory immune response and an improved control of
S. typhimurium septicemia. Second, iron exerts multiple effects
on immune effector functions. This is on the one hand based
on the role of iron for the differentiation and proliferation of
immune cells, including antigen presenting cells and lympho-
cytes (reviewed by Oppenheimer, 2001; Weiss, 2002; Cairo et al.,
2011). Moreover, iron affects anti-microbial immune function of
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FIGURE 1 | Iron homeostasis in differently regulated depending on the
primary localization of the pathogen. During an inﬂammatory process
cytokines and bacterial products can induce the formation of the master
regulator of iron homeostasis, hepcidin, in the liver. (A) In case of infection
with extracellular bacteria hepatocyte derived hepcidin targets ferroportin
(FP1) on the cell surface and results in its degradation thereby reducing
macrophage iron agrees. This effect is further supported by minute
amounts of hepcidin produced by macrophages in response to interleukin-6
(IL-6) and by the action of interferon-gamma (IFN-γ) which inhibits ferroportin
expression transcriptionally. This results in systemic hypoferremia and
reduced iron availability for extracellular bacteria whereas the increased
intracellular amounts of iron in the cell are incorporated into ferritin, the
expression of which is induced by iron and cytokines, such as tumor
necrosis factor-alpha (TNF-α), IL-1β, or IL-6. (B) While in case of an infection
with intracellular bacteria hepcidin also exerts negative effects on ferroportin
expression posttranslationally, this mechanisms appears to be outcompeted
by massive induction of ferroportin transcription which can be traced back
to activation of inducible nitric oxide synthase (iNOS) with subsequent nitric
oxide (NO) formation and activation of the transcription factor Nrf2 which
massively stimulate ferroportin transcription leading in summary to
stimulation of iron export and reduction of intracellular iron levels. In
addition, microbes residing in the phagolysome are further deprived from
iron via the action of Nramp1 which pumps the metal into the cytoplasm
and subsequently out of the cells by the action of ferroportin. In addition,
due to the negative regulatory effect of iron on innate immune effector
function and speciﬁcally IFN-γ activity, the reduction of intracellular iron
levels results in stimulation of anti-microbial immune effector pathways,
such as iNOS, TNF-α, or IL-12 formation which together with the reduction
of cellular iron availability help to control infections with intracellular
microbes.
macrophages via inhibition of IFN-γ inducible effector pathways
(Weiss et al., 1992; Oexle et al., 2003). Thus, macrophages loaded
with iron lose their ability to clear infections with intracellular
pathogens, such as Salmonella,Mycobacteria,Chlamydia,Candida,
orLegionella (Mencacci et al., 1997; Chlosta et al., 2006; Nairz et al.,
2007; Paradkar et al., 2008; Botella et al., 2012; Bellmann-Weiler
et al., 2013) whereas reduction of iron levels or addition of iron
chelators can improve infection control by withholding iron from
microbes and by increasing anti-microbial immune effector func-
tions. Thereby iron chelators antagonize a direct inhibitory effect
of iron toward the expression of iNOS (Weiss et al., 1994; Melillo
et al., 1997; Dlaska and Weiss, 1999). iNOS catalyzed high output
formation of the labile radical NO by macrophages (Nathan and
Shiloh, 2000; Bogdan, 2001) which exerts direct anti-microbial
effector functions. This pathway appears to be partly responsi-
ble for the beneﬁcial clinical effects of iron chelators observed
in several experimental infection systems (Mencacci et al., 1997;
Fritsche et al., 2001; Ibrahim et al., 2007; Bellmann-Weiler et al.,
2013; Nairz et al., 2013). Along this line children suffering from
cerebral malaria beneﬁted from the addition of the iron chelator
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desferrioxamine to a standard anti-malaria treatment, as reﬂected
by faster recurrence from coma and clearance of plasmodia,
although this did not translate into a survival beneﬁt (Gordeuk
et al., 1992; Mabeza et al., 1999), although anti-plasmodial innate
immune responses were positively affected by iron chelation in
vivo (Thuma et al., 1996; Weiss et al., 1997b). Of interest, via its
inhibitory potential on IFN-γ iron affects T-helper (TH) cell dif-
ferentiation favoring the expansion of TH-2 cells which produce
a number of macrophage-deactivating cytokines such as IL-4 or
IL-13 (Weiss, 2002). Accordingly, iron overload and iron chelation
have been shown to modulate the TH-1/TH-2 in mice exposed
to different microbes (Mencacci et al., 1997; Ibrahim et al., 2007;
Nairz et al., 2013). However, a recent clinical trial in patients after
allogenic bone marrow transplantation who received the iron
chelator desferrasirox in an attempt to improve the control of
mucormycosis, a devastating invasive fungal infection in severely
immuno-compromised patients, failed to show a clinical beneﬁt
(Spellberg et al., 2012). In contrast, the mortality rate was even
higher in those subjects receiving desferrasirox and the reason for
that has been elusive thus far. Hypothetically this may be partly
related to an effect of desferrasirox on innate immune function,
which could have been resulted in aggravation of graft versus host
disease, a notion which should be veriﬁed at least retrospectively.
However, from all the evidence listed above it appears obvious
that ACD develops from the endeavor of the body to withhold
iron from invading, extracellular pathogens and to strengthen at
the same time anti-microbial immune responses (Figure 1A).
Accordingly, clinical trials which were performed to supple-
ment iron to children in developing countries based on the notion
that iron deﬁciency is associated with growth and mental retar-
dation produced unpredicted results (Schumann et al., 2007).
These studies demonstrated that iron supplementation resulted
in higher incidence of or higher mortality from infections such
as malaria, diarrhea or bacterial meningitis (Sazawal et al., 2006;
Sooﬁ et al., 2013). The pathways underlying these devastating out-
comes remain elusive thus far. However, theymay be linked to iron
mediated modulation of anti-microbial immune defense mecha-
nisms or traced back to increased availability of the metal for
pathogens in the setting of subclinical parasitemia or bacteremia.
The cause-effective association between iron availability and the
clinical course ofmalaria has beenwell establishedby several recent
studies.
Those studies provided evidence for a reduced risk of malaria
in general and severe malaria in iron deﬁcient pregnant women
and children (Kabyemela et al., 2008; Gwamaka et al., 2012; Jonker
et al., 2013) whereas other studies found interesting associations
between iron delivery for erythropoiesis, circulating hepcidin lev-
els and the prevalence of malaria in tropical countries (de Mast
et al., 2010; Prentice et al., 2012; Atkinson et al., 2014).
Apart from plasmodia, the availability of iron is of importance
for other parasitic infection such as Leishmaniosis or Trypanoso-
miasis. The pathogenicity of Leishmania is linked to the expression
of different microbial iron acquisition molecules and a sufﬁ-
cient supply of iron (Mittra et al., 2013). Accordingly, inhibition
of cellular iron export can promote Leishmania proliferation
(Ben-Othman et al., 2014) whereas over-expression of ferroportin
with subsequent limitation of intracellular iron availability limits
intracellular leishmanial growth (Raﬁee et al., 2014). In addi-
tion, drugs such as quercetin exert their anti-microbial activity
against Leishmania donovani by interfering with microbial iron
acquisition (Sen et al., 2008). Of note, L. donovani manipulates
macrophage iron homeostasis to increase its own iron supply
(Das et al., 2009). However, via its radical promoting capacity
iron can also exert protective effects in Leishmania infection by
strengthening radical dependent host response as shown in a
mouse model of Leishmania infantum infection (Vale-Costa et al.,
2013). Similarly, Trypanosma species are also highly dependent
on a sufﬁcient supply of iron which depending on the sub-
type is acquired by classical sources (transferrin) or taken up
via ZIP family transporters (Taylor and Kelly, 2010). Given the
central role of iron for the pathogenesis of trypansoma infec-
tions, the host aims at limiting iron availability to these parasites
which results in alterations of macrophage iron homeostasis along
with the development of anemia (Stijlemans et al., 2008, 2010).
Of interest, the induction of the Nrf2 pathway exerted protec-
tive effects in a model of Trypanosma cruci infection in mice
which was counterbalanced by the addition of iron sulfate (Paiva
et al., 2012), suggesting that Nrf2 exerted its anti-trypanosmal
activity by increasing the expression of ferroportin (Nairz et al.,
2013).
METABOLIC IRON RESPONSES AND IMMUNE CONTROL OF
INTRACELLULAR PATHOGENS
Although still insufﬁciently understood, it is hypothesized that the
presence of extracellular pathogens in the circulation induces iron
restriction in the monocyte/macrophage system via the action of
hepcidin and several cytokines, whereas the metabolic responses
to intracellular microbes appear to be different (Figure 1).
Macrophages infected with S. typhimurium increase the expres-
sion of ferroportin and stimulate iron export (Nairz et al., 2007).
This leads to a reduced availability of iron for intracellular bacte-
ria along with an activation of anti-microbial immune effector
mechanisms due to counter-balancing the negative regulatory
effects of iron on IFN-γ inducible immune pathways (Oexle et al.,
2003; Nairz et al., 2007; Weiss and Schett, 2013). Similar obser-
vations have been made with other intracellular pathogens such
as Chlamydia spp. or Legionella (Chlosta et al., 2006; Paradkar
et al., 2008; Bellmann-Weiler et al., 2010) Of interest, ferroportin
is also expressed in mycobacteria containing phagosomes where
it pumps iron into the cytoplasma (Van Zandt et al., 2008), a
pathway which limits the availability of this essential nutrient
for this bacterium (Schnappinger et al., 2003; Olakanmi et al.,
2013). This indicates that the stimulation of iron export via fer-
roportin is an efﬁcient defense strategy against infection with
intracellular microbes by limiting their access to iron and by
strengthening anti-microbial immune effector pathways (Nairz
et al., 2010).
Recent evidence suggest, that the intracellular bacterium
Salmonella typhimurium can counteract these metabolic immune
defense strategies by inducing hepcidin expression in hepatocytes
via activation of estrogen related receptor (ERR)-gamma, thereby
resulting in hypoferremia and macrophage iron retention with a
subsequently increased availability of the metal for intracellular
Salmonella (Kim et al., 2014). A reverse agonist of this pathway
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counter-acting ERR-gamma and hepcidin mediated macrophage
iron retention led to an improved control of Salmonella infection
(Kim et al., 2014). This is in a line with previous observations
demonstrating that modulation of the hepcidin/ferroportin axis
impacts on intracellular proliferation of Salmonella and the course
of infection in mice (Nairz et al., 2009b; Wang et al., 2009).
Importantly, several innate resistancemechanisms exert at least
part of their anti-microbial activity via restriction of iron to
microbes.
NO
High output formation of NOby immune cells is of central impor-
tance for immune control of infections and cancer (Nathan and
Shiloh, 2000; Bogdan, 2001). An interaction of NO with iron
homeostasis has been well documented based on the fact that
(i) NO has a high afﬁnity for iron and that many of the cytotoxic
effects of NO are based on targeting of central iron sulfur clus-
ters in enzymes by the labile radical (Nathan and Shiloh, 2000;
Bogdan, 2001), that (ii) NO controls intracellular iron trafﬁck-
ing by regulating the binding afﬁnity of iron regulatory proteins
(IRP) to speciﬁc RNA stem loop structures within the non-coding
regions of critical iron metabolism genes (Drapier et al., 1993;
Weiss et al., 1993; Pantopoulos et al., 1996), and ﬁnally, that (iii)
cellular iron content controls NO expression by regulating iNOS
transcription (Weiss et al., 1994; Melillo et al., 1997; Dlaska and
Weiss, 1999). Recent evidence now suggests that part of the anti-
microbial effect of NO can be attributed to a regulatory activity of
the radical on iron homeostasis. Thereby, NO activates the bind-
ing afﬁnity of the transcription factor Nrf-2 to the ferroportin
promoter, resulting in increased ferroportin expression and iron
export (Nairz et al., 2013). This results in a reduced availability of
iron for intra-macrophage bacteria and a strengthening of anti-
microbial, IFN-γ driven immune responses. Of note, iNOS−/−
mice present with macrophage iron overload and their resistance
against infection with Salmonella can be increased upon applica-
tion of a membrane permeable iron chelator such as desferrasirox
(Nairz et al., 2013).
Nramp1
The natural resistancemacrophage protein 1 (Nramp1 or Slc11a1)
has been characterized as a late phagosomal protein conferring
resistance to infection with Salmonella, Mycobacteria, and Leish-
mania (Blackwell et al., 2000; Forbes and Gros, 2001). Nramp1
exerts its protective effect against such infections via acidiﬁca-
tion of the microbe containing phagosome, but also by altering
the cellular distribution of divalent metals such as zinc, man-
ganese or iron which all play decisive role in host–pathogen
interaction (Hood and Skaar, 2012; Diaz-Ochoa et al., 2014).
In addition, the functional expression of Nramp1 strength-
ens anti-microbial immune effector pathways such as the for-
mation of TNF-α or NO (Barton et al., 1995; Fritsche et al.,
2003). These effects can be traced back to prolonged activ-
ity of pro-inﬂammatory signaling pathways and inhibition of
the expression of anti-inﬂammatory cytokines, such as IL-10
(Fritsche et al., 2008). Evidence accumulates, that Nramp1pumps
iron out of macrophages thereby reducing iron levels in the
cytoplasma and within the phagolysosome rendering the metal
less available for intracellular bacteria (Barton et al., 1999; Zwill-
ing et al., 1999; Kuhn et al., 2001; Nairz et al., 2009a; Sohn
et al., 2011). As a further consequence of intracellular iron
depletion, pro-inﬂammatory immune effector pathways are
augmented. One of these Nramp1-inducible responses is the
increased formation of lipocalin-2 (Lcn2 or NGAL), which
blocks another source of iron for bacteria (Fritsche et al.,
2012).
LIPOCALIN-2
Lcn2 is produced by several cells in the body including neutrophils
and macrophages (Chakraborty et al., 2012). Among many other
functions it binds the bacterial siderophore enterobactin, which
is produced by Gram-negative bacteria such as Escherichia coli,
Klebsiella, or Salmonella spp. to scavenge iron and to redeliver
the metal to the microbe where it is taken up via speciﬁc recep-
tors. Mice expressing Lcn2 are more resistant to infections with
such Gram-negative bacteria as compared to Lcn2−/− littermates
which is cause-effectively due to the bacterial iron withholding
capacity of Lcn2 (Flo et al., 2004; Berger et al., 2006). Of note,
the varying dependence of bacteria from siderophore mediated
iron uptake can cause a growth advantage of certain bacteria
among others. It has recently been demonstrated that the pro-
biotic bacterium E. coli Nissle controls the growth of pathogenic
Salmonella in the intestine by over-coming iron restriction by
Lcn2 (Deriu et al., 2013). Accordingly, resistance of Salmonella
to Lcn2 mediated iron restriction can cause a growth advantage of
this pathogen in the gut (Raffatellu et al., 2009). It is of interest,
that Lcn2 not only affects microbial iron delivery but also host
iron homeostasis. This is most likely due to binding of a recently
identiﬁed mammalian siderophore by Lcn2 which then can shut-
tle iron across cellular membranes (Bao et al., 2010; Devireddy
et al., 2010). Of note, recent evidence also suggests that the mam-
malian siderophore 2,5-DHBA can be utilized by Gram-negative
bacteria as a source of iron and that macrophages reduce the
expression of 2,5-DHBA when exposed to LPS or Gram neg-
ative bacteria which is also considered to be part of the “iron
withholding” defense network of innate immune cells (Liu et al.,
2014).
Lcn2 appears to be of importance to mount alterations of
iron host homeostasis on the cellular and systemic level thereby
contributing to hypoferremia and intracellular iron depletion
in systemic Salmonella infection (Nairz et al., 2009b; Srinivasan
et al., 2012). An increased expression of Lcn2 by macrophages
along with reduced intramacrophage iron content and impaired
bone morphogenetic signaling may be largely responsible for the
reduced susceptibility of Hfe−/− mice, a model for hereditary
hemochromatosis, against infection with the intracellular bacte-
ria Salmonella and Mycobacteria (Olakanmi et al., 2007; Corradini
et al., 2009; Nairz et al., 2009b), which may also be a reason of
the high penetrance of this genes in people of Northern and
Western European origin (Pietrangelo, 2004). Accordingly, Lcn2
expression positively affects the course of infection with other
intracellular pathogens, even if they do not express siderophores
such as Chlamydia (Bellmann-Weiler et al., 2013), whereas cel-
lular iron export and increased delivery of the metal to the
extracellular space can be detrimental as observed in a model
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of pneumococcal infection, where Lcn2 expression by neu-
trophils resulted in increasedmortality of mice (Warszawska et al.,
2013).
This again provides evidence that contrasting pathways for the
regulation of iron homeostasis according to infection with either
intracellular or extracellular pathogens exist (Chan et al., 2009;
Warszawska et al., 2013; Fang and Weiss, 2014) which are still
insufﬁciently understood (Figure 1).
Owing to the importance of these pathways for immune
defense against infection with intracellular pathogens the cen-
tral TH-1 cytokine IFN-γ exerts part of its anti-microbial effects
by stimulating immune responses which restrict the availabil-
ity of iron for microbes. IFN-γ induces the expression of
Nramp1, Lcn2, and NO thereby reducing intracellular iron con-
tent in macrophages and limiting the growth of bacteria such as
Salmonella (Gruenheid et al., 1997; Fritsche et al., 2008; Nairz et al.,
2008, 2009a; Andrews-Polymenis et al., 2010; Nairz et al., 2013).
Thus, IFN-γ is central for host response in Salmonella infection
based on these nutritional iron effects but also due to its abil-
ity to induce a myriad of anti-bacterial effector mechanisms in
macrophages including oxygen and nitrogen radical formation
or maturation of the bacterial containing phagosome (Mastroeni
et al., 2000; McCollister et al., 2005; Henard and Vazquez-Torres,
2011). Of note, neutrophils have recently been shown to produce
IFN-γ to further stimulate anti-bacterial immune pathways (Spees
et al., 2014) whereas S. typhimurium has been shown to impair the
proliferation of CD4 cells, a major source of IFN-γ (Atif et al.,
2014).
TARGETING IRON HOMEOSTASIS IN INFECTIOUS
DISEASE-TO WALK A TIGHTROPE
While iron supplementation in eras with a higher burden of infec-
tious diseases caused detrimental effects toward the risk of malaria
or invasive bacterial infections (Sazawal et al., 2006; Sooﬁ et al.,
2013), iron supplementation in HIV infected patients resulted in
an impaired control of malaria but also in a beneﬁcial or at least
neutral course of HIV infection at as reﬂectedbyCD4+-cell counts
or progression of the disease which was partly dependent on the
degree of anemia and base-line iron status (Esan et al., 2013; Pren-
tice et al., 2013; Zlotkin et al., 2013). However, HIV infection is
often associated with reactivation of Mycobacterium tuberculosis
infection, and iron has been shown to be an essential nutrient
for such bacteria which goes along with the observation that iron
loading is associated with an increased risk for tuberculosis and an
adverse clinical course of this infection (Moyo et al., 1997; Gan-
gaidzo et al., 2001; Schaible and Kaufmann, 2004). Accordingly,
iron supplementation in subjects with latent tuberculosis and an
impaired immune control, e.g., on the basis of HIV infection,
is hazardous (McDermid et al., 2013). Of interest, a recent study
suggested that both, iron deﬁciency and iron loading, are associ-
ated with an adverse clinical course of tuberculosis, both in HIV
positive and negative subjects (Isanaka et al., 2012a,b). This may
relate to the divergent effects of iron on the immune system, on the
one hand iron is a prerequisite for immune cell proliferation and
differentiation (Thorson et al., 1991; Weiss, 2002; Porto and De
Sousa, 2007), and a catalyzer for the formation of anti-microbial
radicals (Mastroeni et al., 2000; Papanikolaou and Pantopoulos,
2005), whereas on the other hand it impacts on innate immune
effector functions (Weiss and Schett, 2013) and positively affects
microbial proliferation (Schaible and Kaufmann, 2004;Weinberg,
2009; Nairz et al., 2010; Cassat and Skaar, 2013; Figure 1B). Thus,
a certain balance of iron, not too less and not too much, is needed
to strengthen immune responses to successfully combat infec-
tions (Drakesmith and Prentice, 2012). Of note, alterations of
iron homeostasis have been shown to affect the composition of
the human microbiome and may thereby alter the proliferation of
pathogenic bacteria (Deriu et al., 2013).
Accordingly, pharmacological concepts to modify iron home-
ostasis and iron trafﬁcking in an attempt to combat infection have
always to keep in mind that a positive effect on one infection
may have devastating effects on the course of another infection as
seen in models of malaria where tolerance induction via overex-
pression of HO improves the course of malaria but increases the
risk for bacterial infections such as Salmonellosis (Portugal et al.,
2011; Gozzelino et al., 2012). Opposite, reduction of intracellu-
lar/macrophage iron levels upon therapeutic application of the
calcium-antagonists nifedipine resulted in signiﬁcantly improved
survival of mice with S. typhimurium (Mair et al., 2011). Strictly
speaking, any therapeutic strategy, e.g., iron chelation, iron mobi-
lization, hepcidin or anti-hepcidin pharmacological approaches,
which help to control the course of one, e.g., intracellular infec-
tion, may increase the availability of iron for a pathogen residing
in a different compartment, e.g., in the extracellular space, along
with the unpredictable effects on host immune response (Nairz
et al., 2010; Drakesmith and Prentice, 2012). Thus, major research
efforts must be undertaken to better understand the diverse roles
of iron in infection and in immune control of infections. Specif-
ically, we also need to address the metabolic alterations of iron
homeostasis in response to different pathogens, not only in terms
of their primary tissue localization but also in relation to their
needs for iron and the immune mechanisms being involved in
their control.
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